The trademark application SynOx was filed by Synox Therapeutics Limited, a corporation established under the laws of Ireland (the "Applicant"). The application was published for oppositions on June 24, 2021, and it was registered by office on September 30, 2021 without any oppositions.
The application was filed in English (Spanish was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on August 10, 2021. Appointment and Replacement of representative of the trademark registration was recorded on August 17, 2021. Creation of rights in rem of the trademark registration was recorded on April 29, 2024.
Goods And Services
The mark was filed in class 5 with following description of goods:
Humanised antibody-based drugs for the treatment, diagnosis, detection and/or prevention of cancer and/or other diseases
Humanised antibody emactuzumab targeting the CSF1R (colony stimulating factor 1 receptor) in cancer
Inhibitors of CSF1R and macrophage function for the treatment of cancer and/or other diseases
Inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of TGCT (tenosynovial giant cell tumour) / PVNS (pigmented villonodular synovitis)
Compounds for the treatment, diagnosis, detection and/or prevention of cancer and/or other diseases
Pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other diseases
Biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other diseases.